A thyroid hormone antagonist has not been previously described. A number of thyroid hormone analogues have been shown to compete with ["25Iltriiodothyronine (1125I1T3) for bind-ing to the intranuclear thyroid hormone receptor and to have agonist activity proportional to their affinities for the receptors. We report that the benzofuran amiodarone acts as a competitive antagonist to thyroid hormone action as defined by its dose-dependent ability to (a) bind to the thyroid hormone receptor and (b) inhibit T3-induced increases in growth hormone mRNA levels in a cultured rat pituitary cell line, GC cells. Like T3 itself, amiodarone also decreases transport of 112511T3 across GC cell membranes. An analysis of the amiodarone structure suggests that this compound has certain similarities to T3. These findings hold promise for the development of other thyroid hormone antagonists for clinical use and for understanding thyroid hormone action.
Introduction
Most cell receptors for small organic molecules have a developed pharmacology of agents that act as agonists or antagonists. For example, suitable antagonists can block the actions of dopaminergic, alpha and beta adrenergic, and cholinergic agonists (1) . Antagonists have been described that interact with the mineralocorticoid, glucocorticoid, estrogen, and progesterone receptors (1) . It is surprising, however, despite extensive structure activity studies conducted over the past 20 years (2, 3) , no antagonist for thyroid hormone receptor action has been identified.
Amiodarone is a benzofuran (2-butyl-3-[3,5-diiodo-4-(fldiethylaminoethoxy)-benzoyl]benzofuran) widely prescribed for the treatment of ventricular and supraventricular arrhythmias (4, 5) . Chronic administration of amiodarone has been associated with both hyper-and hypothyroid-like side effects. The drug has also been reported to cause changes in the concentrations of serum thyroxine (T4) and triiodothyronine (T3) levels, which have been attributed to an inhibition of peripheral T4 monodeiodination, and to iodine-induced changes in glandular hormonogenesis (6, 7) . However, cases of clinical hypothyroidism have occurred, often with mildly elevated thyroid-stimulating hormone (TSH) and normal T4 and T3 levels, and in vitro studies have suggested an amiodarone-induced with 0.4 M KC1. Livers and brains were from euthyroid rats, which were obtained from Rockland, Inc. (Gilbertsville, PA). Solubilized receptors from GC cells were prepared as follows: confluent 150-cm2 culture plates were rinsed for 5 min with PBS (37°C), then scraped with a rubber policeman in 5 ml PBS (4°C). The 1,000 g cell pellet was suspended in 10 ml solution A, on ice [20 mM KPO4, pH = 7.6; 4mM EGTA; 4 mM MgCl2; 0.25 M sucrose; 0.5% NP-40; 0.5 mM PMSF; 0.1% monothioglycerol (MTG)']. Cells sat on ice for 3 min, followed by a second spin. The resulting cell lysate was washed with solution A minus NP-40, pelleted again, and resuspended in 10 ml of solution B (20 mM KPO4, pH = 7.2; 10 mM EDTA; 2 mM MgCl2). The nuclei were gently mixed and allowed to sit at 4°C for 30 min. This suspension was then centrifuged (300 g, 10 min), and the resulting chromatin pellet was washed twice in 10 ml of solution C (10 mM KPO4, pH = 7.2; 1 mM MgCI2; 0. 1% MTG). The washed pellet was then solubilized in 2 ml ofsolution D (I0mM Tris; 1 mM MgCl2; 0.5 mM EDTA; 400 mM KCl; 10% glycerol; 0.1% MTG; pH = 7.6). The chromatin was then sonicated in this solution (30 1-s pulses) . After a 30-min incubation on ice, polyethyleneimine (PEI) was added to a final concentration of 0.01% and the solution stirred gently for 5 min. Following centrifugation at 15 ,000 g for 15 min the supernatant was adjusted to 3% PEG, 0.02% PEI, and 20 mM KPO4. After 20 min on ice this suspension was centrifuged again (15, Sephadex. Receptor concentrations were 150-300 pM. L-T3 was from Aldrich Chemicals (Milwaukee, WI). A 1-mM stock was prepared in MeOH containing 1% NH40H. This was diluted in 0.1 mM NaOH and added directly to binding and culture assays. Amiodarone-HCl was obtained in liquid form (Cordarone; Labaz, France) or as a purified powder (Sanofi Chemicals, Montpellier, France). The liquid form was supplied at 73 mM in a vehicle consisting of(vol/vol) 88.8% H20, 9.3% Tween 80, 1.9% benzyl alcohol. The powder was prepared fresh at 14 mM in EtOH:10 mM HCI (1:1). Dilutions from both solutions were prepared in 1 mM HCL. Control experiments were carried out in the presence of appropriate vehicles, which had no effect on binding reactions. Preliminary experiments suggested that the powdered form, prepared and diluted as described, did not affect intact, cultured GC cells in a manner identical to the liquid form, probably because of solubility problems. For established, cells were washed thoroughly in PBS, and whole-cell radioactivity was determined. Cell nuclei were then prepared by lysis in situ and specific nuclear binding determined according to established methods for pituitary tumor cells (13) . Binding in each nuclear pellet was normalized to DNA content (14) . ['251I]T3 radioactivity was also determined in the supernatant ofthe nuclear pellet. For the purposes of this study the supernatant, which contained cytosol and lysed cellular membranes, was termed cytosol. In separate experiments, GC cells were cultured as described except in the presence of 1. (12-18 h ), GC cells were cultured for 2-4 d in 20 ml of DME containing 10% serum substitute solution plus 2% stripped serum (9) . Media were replaced after the second day of culture. It has been demonstrated previously (17, 18 ) that 2-4 d of culture under "hypothyroid" conditions ("deinduction") produce baseline levels of rGH mRNA in pituitary tumor cells. In one set of experiments, cells were deinduced for 4 d, then cultured for an additional 2 d in stripped media containing: (a) 300 pM T3 plus varying concentrations ofamiodarone, or (b) no additional treatment (Fig. 4) . In a second set of experiments, they were deinduced for 48 h, then cultured for an additional 48 h in stripped media containing 3.2 MM amiodarone plus varying concentrations of T3 (Fig. 5) . Total cytoplasmic (19) or total cellular (20) mRNA were prepared as described. The amount of rGH message present in aliquots of GC cell cytoplasm was determined by Northern hybridization using glyoxylated RNA (21) . Equal amounts of cytoplasmic RNA were examined per lane (15 or 20 ag). HeLa cell RNA also was tested as a control for specificity and background binding. The rGH message was detected by hybridization with the 0.8 kb pRGH-I rat growth hormone cDNA (22) . Some blots were also probed with a 1.6 kb Xho I fragment of the pHFl human y-actin gene (23 
Results
The characteristics of binding by T3 to its nuclear receptor were first determined using crude preparations of KCl-solubilized rat liver nuclei. In these assays, T3 bound to a single class ofsites with high affinity (weighted mean ofsix determinations (Kd = 359 pM; range 189-630 pM). The Kd value of 359 pM was derived from nonlinear least-squares regression analysis of experimental data (15, 16) and was used as an initial estimate of receptor affinity in subsequent analyses of binding assays. Affinities were similar for receptors from solubilized GC cell nuclei and from cultured GC cells (560 and 470 pM, respectively). The results for solubilized hepatic receptors are similar to those reported previously (25, 26) .
In a variety of solubilized receptor preparations, amiodarone competed with T3 for binding to a single class of sites in a dose-dependent fashion at concentrations from 0.1 to 100 mM ( Fig. 1 a) . For rat liver-derived receptor, the 50% inhibition (EC50) occurred at 3 ,uM amiodarone, and 80% inhibition was at 50 MM. Amiodarone rarely produced > 80% inhibition of [125IJT3 binding in these preparations. This is probably due to the poor solubility of the drug in high ionic strength buffers (27), which results in precipitates at higher concentrations. The calculated affinity of the receptor for amiodarone in this experiment expressed as the Kd was 1.4 MM. Amiodarone also competed with [ ( Fig. 2 A) The effects of T3 and amiodarone on cellular equilibrium levels of ['25I]T3 were examined in cultured GC cells (Fig. 3) . Both competitors caused parallel, dose-dependent decreases in radioactivity in whole cells and cytosol. In addition, the maximum decrease in both cellular and cytosolic radioactivity was -45-50% in response to either competitor. This result is in contrast to those obtained from GC cell nuclei, where radioactivity decreased by -75 and 95% in response to increasing concentrations of amiodarone and nonradioactive T3, respectively.
Cultured GC cells were utilized to assess the effect of amiodarone on T3 action. These cells respond to T3 by increasing their synthesis of rat growth hormone (rGH) due to increases in rGH mRNA resulting from transcriptional activation ofthe growth hormone gene (18, 28) . As shown in Fig. 4 A, amiodarone blocked the induction of rGH mRNA by 300 pM T3 as analyzed by RNA blot (Northern) analysis. In three experiments RNA was normalized by loading equal amounts (15 or 20 ytg) ofcytoplasmic RNA per lane, and equivalency of loading was verified by visualization of 18S and 5S rRNA by ultraviolet shadowing. As a further control, RNA content was normalized to human gamma-actin mRNA in an additional experiment with identical results. Autoradiographs were analyzed by densitometry, and arbitrary densitometric units were used to construct amiodarone competition curves. Fig. 4 B (open circles) displays an amiodarone mRNA competition curve that represents a composite of four experiments. The EC50 for blockade of rGH mRNA by amiodarone under these conditions was 3.1 ,uM, very similar to the EC50 for binding to the thyroid hormone receptor of these cells in the presence of 300 pM T3 (3.3 uM) and is consistent with the Kd for binding Fig. 4 B. The slope factor of the composite curve did not differ significantly from 1.0, again suggesting that amiodarone's effects on rGH mRNA are directly mediated by its interaction with a single class of nuclear receptor binding sites (see Table I ). Since amiodarone displayed competitive binding to solubilized T3 receptors (Fig. 2) , we tested whether its inhibitory effects on rGH mRNA could be overcome by T3. GC cells were deinduced 2 d, then treated with 3.2MgM amiodarone plus varying concentrations of L-T3. After 24 h of culture, total cellular mRNA was quantified as described previously. In the absence ofT3, amiodarone produced no effect on rGH mRNA (Fig. 5) . GC cells exposed to 300 pM T3 in the absence of amiodarone had rGH mRNA levels about threefold greater than those in untreated cells, while amiodarone caused a reduction in mRNA levels under these conditions. Fig. 5 also demonstrates that a saturating dose of T3 (5 nM) was able to overcome the inhibitory effects of amiodarone. (29) reported that amiodarone acts as a competitive inhibitor to T3 binding in solubilized rat liver nuclear receptors. However, a more recent study (30) reported that amiodarone possessed no competitor activity in solubilized rat liver receptors. In cell culture studies, amiodarone did not inhibit hormone binding to rat hepatic nuclei (31) GC cells. After treatment with T3 and graded doses of amiodarone, cytoplasmic RNA was prepared and analyzed by Northern hybridization as described in Methods. After hybridization, blots were autoradiographed and analyzed using a Zeineh scanning densitometer. Arbitrary density units were used to construct competition curves and to derive EC50 values and slope factors for amiodarone's effect on rGH mRNA accumulation (15, 16) . The "100%" point on the curve represents data from cells treated with 300 pM T3 without amiodar- increases in basal TSH release (7), decreases in malic enzyme and a-glycerol-phosphate dehydrogenase in rat liver (33) , decreased rat serum triglycerides (34) , and decreased cardiac myosin activity, an enzyme that is known to be induced by thyroid hormone (35) . In cell culture studies amiodarone reduced T3-induced increases in [3H]thymidine incorporation into GH3 cells (36) and increased TSH release from cultured rat anterior pituitary cells (8) .
Franklyn et al. (37) observed confficting effects of in vivo administered amiodarone on mRNA levels for T3-responsive genes in rats. Thus, amiodarone caused increases in pituitary TSH a and (# subunit mRNAs, consistent with a direct antagonistic effect of amiodarone to thyroid hormone action at the receptor level. However, no effect was observed on rGH mRNA levels. It is surprising that in hypothyroid rats, amiodarone exhibited T3 agonist-like activity, causing decreased levels of TSH mRNA and increases in rGH mRNA. The reason for these disparate results was not fully resolved by the authors. However, hormonal interactions in vivo are much more complex than those observed under cell culture conditions, and comparisons between these approaches must be made with caution. Nevertheless, in our cell culture studies, we observed no evidence for T3 agonist-like effects ofamiodarone.
Under "hypothyroid" cell culture conditions, amiodarone produced no significant effect on rGH mRNA.
Prolonged (24 h or more) incubation of GC cells with lo-'
M amiodarone, an amount that precipitates under culture conditions, reduced cell viability, which is an effect observed by others (36) . However, decreases in rGH mRNA levels are not due to nonspecific effects of amiodarone since the antagonist was selective for rGH mRNA, and amiodarone at 10 /AM was unable to reduce rGH mRNA levels below baseline. Further experiments revealed that 5 nM T3 abolished the effects of amiodarone (Fig. 5) . Finally, when amiodarone-treated cells are cultured in fresh media containing FCS, growth and rGH mRNA levels are restored (data not shown); an effect that is to be expected of a hormone antagonist (38) . Cellular and nuclear transport systems for thyroid hormones have been described, but studies have not yielded consistent data in the hands of all investigators. A nonsaturable, stereo-specific, T3 uptake system has been described for rat hepatocytes by Oppenheimer (39). Krenning et al. have described a different low affinity, energy-dependent transport system for T3 in rat hepatocytes that, in contrast to that described by Oppenheimer, appears to be inhibited by L-T3 (40) or, when tested at a single dosage and time point, by amiodarone (41) . In addition, rat pituitary tumor (GH,) cells are able to concentrate T3 across the cellular and especially the nuclear membranes (42) and transport into GH, cells appears to be saturable, similar to the effects observed in the present study.
In any case, it might be predicted that a substance that recognizes the nuclear thyroid hormone receptor would interact at other hormone binding sites on or within the cell. Therefore, we asked whether amiodarone altered ['25I]T3 levels in the nonnuclear compartment of GC cells. In our study, both T3 and amiodarone caused a maximum 45 to 50% reduction in total cellular or cytosolic radioactivity in GC cells when assayed at equilibrium with 300 pM [125I]T3. However, a relatively greater reduction in nuclear counts was seen with both amiodarone (75%) and L-T3 (95%). If the competitors were acting solely to inhibit [125I]T3 transport, exactly parallel relative decreases in cellular, cytosolic and nuclear radioactivity would be observed. We also found that the affinity of amiodarone for binding to the thyroid hormone receptor is very similar in solubilized receptor from GC cell nuclei and in nuclear fractions from intact GC cells (Table I) , a result that would be unexpected if amiodarone's blockade of the nuclear thyroid hormone receptor were occurring by different mechanisms in the intact cells and solubilized preparations. In addition, the affinity of T3 for its receptor is essentially the same in whole cells and in solubilized nuclear extracts. Finally, the slope factors (b) for amiodarone's interactions with thyroid hormone receptor preparations from both solubilized tissues and intact cells do not differ from 1.0, consistent with the interpretation that amiodarone interacts with a single class of binding sites in the receptor preparations. Thus, we conclude that both competitors affect equilibrium levels of nonnuclear
[125I]T3 in a parallel manner by altering hormone transport across the cell surface, but both T3 and amiodarone are likely to have additional direct effects on the nuclear thyroid hormone receptor. Indirect support for a nuclear site of action for amiodarone is found in a study by Hostetler et al. (43) , who observed that the cell nucleus contained most of the amiodarone recovered from fractionated lung proteins of drug-treated rats.
Our findings raise the question as to whether the cardiac effects of amiodarone could be due to direct interactions with the T3 receptor. For example, chronic amiodarone treatment causes decreases in both growth rate and cardiac weight in rabbits, and these changes are reversible by T4 administration (44) . In rats, thyroidectomy causes a reduction in heart weight, cardiac CO2 production and myosin Ca2+-ATPase activity. Parallel, although less pronounced, changes are induced by amiodarone. Notably, the effects of both thyroidectomy as well as amiodarone treatment are reversible by thyroid hormone (35) .
Serum levels of amiodarone in humans and rats receiving long-term treatment vary from -1 to 6 uM (45, 46) , which is in the range of Kd values observed in this study. Perhaps of more importance, however, is the fact that amiodarone is concentrated preferentially in certain tissues over time, and it could conceivably accumulate at levels that would allow it to work as a full antagonist (5, 45) . For example, necropsy studies have revealed that liver, lung, and heart preferentially accumulate extraordinarily high concentrations of the drug, containing between 2,600 mg/kg and 200 mg/kg of amiodarone and its metabolite desethylamiodarone; this is far more (40-to 3.5-fold) than that contained by brain or thyroid gland (60 mg/kg) (46) . Pituitary accumulation is unknown. Therefore amiodarone might produce variable in vivo effects on differing tissues based on varying concentrations within the tissue. This could explain why obvious hypothyroidism does not occur in most amiodarone-treated patients, since tissue levels depend on individual patient idiosyncrasy and variation of dose and duration of therapy. Similarly, because of the weak affinity of the drug and its varying tissue absorption, some patients even have symptoms of thyrotoxicosis when iodine induced hyperthyroidism overwhelms the antagonistic properties of amiodarone.
Numerous structure-activity studies have suggested the necessity of bulky iodine or propyl substituents on the outer ring 3' position and the presence of a carboxylic acid group for effective receptor binding and agonist function (2, 47) . Amiodarone possesses neither ofthese moieties, and indeed comparison of the two-dimensional chemical structures reveals no obvious structural similarities between the drugs. To explore a possible structural similarity between T3 and amiodarone, extended conformation molecular models, using standard data sets, were constructed with the MIDAS program at the Computer Graphics Laboratory, University of California, San Francisco (Fig. 6) . posed a remarkable degree ofsimilarity can be seen along their entire "vertical" axes ( Fig. 6 B) . Complete superimposition of the diiodophenyl rings leads to the structures shown in Fig. 6 (43) when used at concentrations 5-10 times greater than that required to inhibit T3 receptor binding by 50%. Finally, the drug has a long half-life and accumulates extensively in tissues; this could hinder the ability to regulate the actions of the drug.
Nevertheless, this study demonstrates that amiodarone interacts directly with the nuclear thyroid hormone receptor, and that it antagonizes the effects of thyroid hormone on rGH message. In addition, it indicates that other amiodarone-like derivatives have the potential to be of considerable practical value both clinically as cardiotherapeutic drugs, and as tools for further investigating the molecular mechanisms of thyroid hormone action.
